Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Classification criteria for psoriatic arthritis: Development of new criteria from a large international study

William J. Taylor, Dafna D. Gladman, Philip Helliwell et al. · Arthritis & Rheumatism · 2006 · 3.7K citations

Medicine, Biostatistics, Clinical Sciences +16

Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation

Craig A. Murphy, Claire L. Langrish, Yi Chen et al. · The Journal of Experimental Medicine · 2003 · 1.6K citations · Full text

Medicine, Immunology, Pathology +17

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

Jonathan Sherlock, Barbara Joyce-Shaikh, Scott Turner et al. · Nature Medicine · 2012 · 1K citations

Veterinary Medicine, Immunology, Pathobiology +13

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths et al. · Journal of the American Academy of Dermatology · 2017 · 860 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Iain B. McInnes, Philip J. Mease, Bruce Kirkham et al. · The Lancet · 2015 · 850 citations

Life Sciences, Immunology, Pharmacotherapy +15